EUCTR2007-001418-17-IT进行中（未招募）不适用
efficacy of treatment with bevacizumab,in the macular degeneration. - ND
AZIENDA OSPEDALIERA DI PADOVA0 个研究点开始时间: 2007年3月29日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •patients whit eging of 50 years affected of maculopatia.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •other cause of maculo patia.non eging.
研究者
相似试验
已完成
不适用
Study on effectiveness of bevacizumab for treatment of radiation necrosis in the brain caused by gamma knife radiation therapyRadiation necrosis in the brainJPRN-UMIN000034959Department of Neurology, Aizawa Hospital5
进行中（未招募）
1 期
Assessment of the efficacy of bevacizumab in combination with Folfiri as second-line treatment after the failure of the cisplatin (or carboplatin)-etoposide combination in patients suffering from an advanced inoperable poorly differentiated neuroendocrine carcinoma of an unknown or gastroentero-pancreatic primary cancer. A phase 2 non-comparative randomized study. PRODIGE 41 - BEVANEC studyeuroendocrine carcinomaMedDRA version: 20.0Level: PTClassification code 10057270Term: Neuroendocrine carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001305-16-FRHospices Civils de Lyon - Direction de la Recherche Clinique et de l'Innovation
进行中（未招募）
1 期
BABH Study: Efficacy and safety of bevacizumab on severe bleedings associated with Hemorrhagic Hereditary Telangiectasia (HHT)EUCTR2017-001031-39-FRHospices Civils de Lyon24
招募中
不适用
A clinical study of Bevacizumab therapy in combination with chemotherapeutic drugs for children with recurrent gliomaJPRN-UMIN000005528Osaka University Graduate School of Medicine12
已完成
2 期
A phase II study for the efficacy of bevacizumab with paclitaxel and carboplatin in patient with stage IVB, recurrent or persistant cervical cancer.Stage IVB, recurrent or persistant cervical cancerJPRN-UMIN000026063Japan Gynecologic Oncology Group:JGOG70